Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $59,960.42 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 2,239 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total value of $59,960.42. Following the completion of the transaction, the insider owned 150,260 shares of the company’s stock, valued at approximately $4,023,962.80. The trade was a 1.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Price Performance

Shares of KALV opened at $26.85 on Friday. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -7.76 and a beta of -0.12. The stock has a 50 day moving average of $22.37 and a 200-day moving average of $17.83. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 52 week low of $9.83 and a 52 week high of $26.87.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $40.86 million during the quarter, compared to the consensus estimate of $39.03 million. As a group, analysts forecast that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on KALV shares. Stifel Nicolaus boosted their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. JonesTrading lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. HC Wainwright lowered KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $37.00 to $27.00 in a research report on Friday, May 1st. Wall Street Zen lowered KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 21st. Finally, Needham & Company LLC lowered KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $30.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL bought a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $24,360,000. Jefferies Financial Group Inc. bought a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $3,494,000. Blue Owl Capital Holdings LP bought a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $1,522,000. Hennion & Walsh Asset Management Inc. raised its stake in KalVista Pharmaceuticals by 93.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 341,819 shares of the specialty pharmaceutical company’s stock valued at $5,520,000 after acquiring an additional 165,236 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ raised its stake in KalVista Pharmaceuticals by 391.9% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 200,991 shares of the specialty pharmaceutical company’s stock valued at $2,449,000 after acquiring an additional 160,128 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.